Status:
COMPLETED
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevan...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS)
- The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study
- All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed
Exclusion
- Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC)
- Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled
- Participation in any other clinical studies
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
March 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05335031
Start Date
March 3 2021
End Date
June 30 2025
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Dresden, MS Ambulanz
Dresden, Saxony, Germany, 01307